Valuation: argenx SE

Market Cap 54.05B 46.79B 43.62B 40.14B 75.73B 5,141B 76.6B 513B 201B 2,571B 203B 199B 8,524B P/E 2026 *
31.3x
P/E 2027 * 25.2x
Enterprise Value 48.64B 42.1B 39.25B 36.12B 68.14B 4,626B 68.92B 461B 181B 2,313B 183B 179B 7,670B EV / Sales 2026 *
7.87x
EV / Sales 2027 * 6.09x
Free-Float
99.98%
Yield 2026 *
0.05%
Yield 2027 * 0.09%
1 day+2.83%
1 week-3.03%
Current month+0.48%
1 month-9.89%
3 months+9.38%
6 months+4.32%
Current year+4.44%
1 week 717.4
Extreme 717.4
770
1 month 717.4
Extreme 717.4
832
Current year 568.4
Extreme 568.4
833.6
1 year 544.2
Extreme 544.2
833.6
3 years 271
Extreme 271
833.6
5 years 224.1
Extreme 224.1
833.6
10 years 12.5
Extreme 12.5
833.6
Manager TitleAgeSince
Chief Executive Officer 47 2026-05-05
Director of Finance/CFO 56 2021-05-31
Chief Tech/Sci/R&D Officer - 2014-12-31
Director TitleAgeSince
Chairman 54 2026-05-05
Director/Board Member 76 2015-05-12
Director/Board Member 65 2016-04-27
Date Insider Type Main position Quantity % Market Cap.
11/23/25 Sell

Director

4,680 0.0076%
11/23/25 Fiscal year

Director

4,680 0.0076%
11/23/25 Fiscal year

Chief Executive Officer

2,000 0.0032%
Change 5-day change 1-year change 3-year change Capi.($)
+2.83%-3.03%+27.40%+67.25% 52.43B
+4.35%+19.90%+60.59%+95.21% 62.53B
+0.91%-0.29%-16.22%-13.43% 23.1B
+0.27%-4.91%-10.99%+350.30% 21.4B
+0.40%+5.29%+30.11%-9.63% 21.17B
+0.75%-0.84%+33.80%-25.25% 17.76B
+9.88%+19.73%+229.67%+385.49% 15.47B
+2.08%-3.28%+21.67%+564.59% 14.68B
+1.25%+0.34%+54.03%+179.72% 14.08B
-2.99%+1.32%+427.85%+174.60% 12.62B
Average +1.97%+3.73%+85.79%+176.88% 25.52B
Weighted average by Cap. +2.48%+4.58%+62.23%+137.12%

Financials

2026 *2027 *
Net sales 6.18B 5.35B 4.99B 4.59B 8.66B 588B 8.76B 58.63B 22.99B 294B 23.22B 22.71B 975B 7.59B 6.57B 6.13B 5.64B 10.64B 722B 10.76B 71.98B 28.23B 361B 28.51B 27.88B 1,197B
Net income 1.85B 1.6B 1.49B 1.37B 2.59B 176B 2.62B 17.54B 6.88B 87.99B 6.95B 6.79B 292B 2.46B 2.13B 1.98B 1.83B 3.45B 234B 3.49B 23.32B 9.14B 117B 9.24B 9.03B 388B
Net Debt -5.42B -4.69B -4.37B -4.02B -7.59B -515B -7.68B -51.36B -20.14B -258B -20.34B -19.9B -854B -7.83B -6.77B -6.32B -5.81B -10.96B -744B -11.09B -74.2B -29.1B -372B -29.39B -28.74B -1,234B
Logo argenx SE
argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises.
Employees
1,863
Date Price Change Volume
26-08-05 €748.60 +2.83% 101,341
26-08-04 €728.00 +0.80% 89,773
26-08-03 €722.20 -3.06% 94,348
26-07-31 €745.00 -0.21% 96,817
26-07-30 €746.60 -3.74% 97,191
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
864.33USD
Average target price
1,036.49USD
Spread / Average Target
+19.92%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ARGX Stock